Evidence map›Paper›PMID 41639663›Full record

Trial reportBMC cancer2026

SCANDARE: an institutional dynamic prospective interventional biobanking study.

Constance Lamy, Léonard Laurent, Olivier Choussy, Nicolas Pouget, Fabrice Lecuru, Fabien Reyal, Anne-Sophie Plissonnier, Amir Kadi, Frédérique Berger, Joey Martin and 31 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03017573 (Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03017573 narecruitingnot on this map

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

TypeinterventionalSponsorInstitut CurieRan2017 to 2032Enrolled1,050ConditionsOvarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer, Cervical CancerArmsTumor biopsies / Tumor surgery, Blood withdrawal
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Constance LamyDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Léonard LaurentDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Olivier ChoussyDepartment of Head and Neck Surgery, Institut Curie, Paris, France.
Nicolas PougetDepartment of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris and Saint-Cloud, France.
Fabrice LecuruDepartment of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris and Saint-Cloud, France.
Fabien ReyalDepartment of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris and Saint-Cloud, France.
Anne-Sophie PlissonnierDREH Pôle Promotion, Institut Curie, Saint-Cloud, France.
Amir KadiDepartment of Biometry, Institut Curie, Saint-Cloud, France.
Frédérique BergerDepartment of Biometry, Institut Curie, Saint-Cloud, France.
Joey MartinDepartment of Head and Neck Surgery, Institut Curie, Paris, France.
Antoine Dubray-VautrinDepartment of Head and Neck Surgery, Institut Curie, Paris, France.
Grégoire MarretDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Edith BorcomanDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Emanuela RomanoDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Marie-Paule SablinDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Luc CabelDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Camille PasquesooneDepartment of Pathology, Oscar Lambret Cancer Centre, Lille, France.
Olivier LantzClinical Immunology Laboratory, Institut Curie, Paris, France.
Delphine LouisClinical Immunology Laboratory, Institut Curie, Paris, France.
Doriane GorretClinical Immunology Laboratory, Institut Curie, Paris, France.
Ines Dias Da SilvaClinical Immunology Laboratory, Institut Curie, Paris, France.
Odette MarianiDepartment of Pathology, Centre Des Ressources Biologiques, Institut Curie, Paris, France.
Olivier DelattreDepartment of Genetics, Institut Curie, Paris, France.
Ivan BiècheDepartment of Genetics, Institut Curie, Paris, France.
Nicolas ServantComputational Oncology, PSL Research University, Mines Paris Tech, INSERM U1331, Paris, 75005, France.
Manuel RodriguesDepartment of Medical Oncology, Institut Curie, Paris & Paris Cité, France.
Jean-Yves PiergaDepartment of Medical Oncology, Institut Curie, Paris & Paris Cité, France.
Romain-David SebanDepartment of Nuclear Medicine, Institut Curie, Saint-Cloud, 92210, France.
Elisabetta MarangoniTranslational Research Department, Institute of Curie, Paris, France.
Antonin MorillonInstitut Curie, CNRS UMR3244, Sorbonne University, PSL University, Paris, France.
Clotilde ThéryInstitut Curie, INSERM U932 and Curie CoreTech Extracellular Vesicles PSL Research University, Paris, France.
Charlotte ProudhonCirculating Tumor Biomarkers Laboratory, SiRIC, Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France.
Eliane PiaggioInstitut Curie, PSL University, Department of Translational Research, Inserm U932, Laboratory of Immunity and Cancer, Paris, F-75005, France.
Céline VallotInstitut Curie, CNRS UMR3244, Sorbonne University, PSL University, Paris, France.
Fatima Mechta-GrigoriouStress and Cancer Laboratory, Institut Curie, INSERM, U830, PSL Research University, Ligue Nationale Contre le Cancer labeled Team, Paris, France.
Julie FlaviusDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Célia DupainDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Géraldine GentricStress and Cancer Laboratory, Institut Curie, INSERM, U830, PSL Research University, Ligue Nationale Contre le Cancer labeled Team, Paris, France.
Anne Vincent-SalomonDepartment of Pathology, Institut Curie, PSL University, INSERM U934, CNRS UMR 3215, Paris, France.
Maud KamalDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France.
Christophe Le TourneauDepartment of Drug Development and Innovation (D3i), Paris-Saclay University, Paris, France. christophe.letourneau@curie.fr.

Funding

Agence Nationale de la Recherche ANR-10-EQPX-03
6 · The paper itself

Abstract

purposeWe set up a prospective longitudinal biobanking study answering scientific questions within a regulatory framework and patient-centered approach. We aim in this paper to present the opportunities of such a study, as well as the challenges and the limitations. PATIENTS AND

methodsSCANDARE (NCT03017573) is an institutional first monocentric then multicentric biobanking study. The study enrolled adult patients with newly diagnosed head and neck squamous cell carcinoma, triple negative breast cancer, ovarian and cervical cancer. All patients signed a consent form before any procedure. Tumor tissue and blood samples are collected at several time points during patient's journey, including at diagnosis, post-neoadjuvant chemotherapy in case of neoadjuvant treatment, at surgery, at recurrence and at disease progression following treatment initiated at recurrence. Clinical data are entered into an eCRF, whereas generated data are centralized in a secure database.

resultsSCANDARE started in 2017 at Institut Curie and has included 676 patients at date. SCANDARE successfully addressed challenges related to patient consent, regulatory compliance, and logistical integration of sample collection into routine clinical practice. The study facilitated the longitudinal collection and preservation of tumor and blood samples, enabling comprehensive analyses from histopathology to genomics and proteomics needed for the 35 ongoing projects run by academic research groups and industry. The implementation of optimized sampling and data workflows enabled high-quality data. Several other cohorts are planned to open soon.

conclusionSCANDARE is an institutional, prospective and dynamic biobanking study that successfully enabled the implementation of 35 research projects with clinical and omics data centralized in a secure database available for all collaborators on demand. Looking ahead, SCANDARE aims to expand its scope by including additional cancer types and patient cohorts, further enhancing the potential for translational research and personalized medicine in oncology.

Indexed as

Biological Specimen BanksHead and Neck NeoplasmsOvarian NeoplasmsUterine Cervical NeoplasmsAdultAgedBreast NeoplasmsFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesBiobanking StudyOncologyPrecision Medicine

Identifiers

PMID41639663
PMCPMC12977387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.